Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Active not recruiting 5Withdrawn 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 6Lung Neoplasms 6Prostatic Neoplasms 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Osteosarcoma 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Barrett Esophagus 3Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Gastroesophageal Reflux 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × Specimen Handling × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡